Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 569.58% and ...

Karen Chung of Chester Springs has received one of the nation’s first treatments for early symptomatic Alzheimer’s disease, ...

The benefits do not stop there. Recent studies suggest GLP-1 drugs may also reduce the risk of heart disease, kidney disease and stroke, and even possibly protect the brain from AD by reducing ...

Some fear weight-loss stocks are approaching bubble territory, but this incumbent player continues to prove its worth ...

There is a higher potential for downside than upside in Biogen Inc's (NASDAQ:BIIB) shares, UBS analysts said Thursday, lowering their price target on the stock from $234 to $202.

Pharmaceutical companies are demonstrating innovation by not only developing new drugs but also exploring combination therapies and repurposing existing drugs to address unmet medical needs.

Eli Lilly, the pharmaceutical giant behind some of the most successful drugs in recent years, has announced plans to invest ...

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Inc. (NYSE: ANVS) today announces its placement in an ...

Kisunla is a 0nce-a-month, 30-minute infusion that is shown to slow the progression of the disease by 37 percent and reduce Alzheimer's-causing plaques by 84 percent.

NEW YORK, Oct. 02, 2024 (GLOBE NEWSWIRE) -- via InvestorWire — Annovis Bio Inc. (NYSE: ANVS) today announces its placement in an editorial published by NetworkNewsWire ("NNW"), one of 60+ ...

Lilly has 11 obesity drugs in its pipeline and wants to develop more treatments for Alzheimer’s disease, ALS and other brain diseases, CEO David Ricks said.

From biochemist to executive supplier to angel investor to company founder and CEO, Maria Maccecchini, Ph.D.’s ...